vs
American Outdoor Brands, Inc.（AOUT）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
American Outdoor Brands, Inc.的季度营收约是REGENXBIO Inc.的1.9倍（$57.2M vs $30.3M），American Outdoor Brands, Inc.净利率更高（3.6% vs -221.3%，领先225.0%），REGENXBIO Inc.同比增速更快（43.0% vs -5.0%），American Outdoor Brands, Inc.自由现金流更多（$-14.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 3.5%）
Deckers Brands（原Deckers Outdoor Corporation）是美国鞋履设计与分销企业，1973年成立，总部位于加利福尼亚州戈利塔，由道格·奥托与卡尔·F·洛普克创立，旗下拥有UGG、Teva、Hoka等多个知名品牌。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
AOUT vs RGNX — 直观对比
营收规模更大
AOUT
是对方的1.9倍
$30.3M
营收增速更快
RGNX
高出48.0%
-5.0%
净利率更高
AOUT
高出225.0%
-221.3%
自由现金流更多
AOUT
多$38.7M
$-52.8M
两年增速更快
RGNX
近两年复合增速
3.5%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $57.2M | $30.3M |
| 净利润 | $2.1M | $-67.1M |
| 毛利率 | 45.6% | — |
| 营业利润率 | 3.7% | -190.0% |
| 净利率 | 3.6% | -221.3% |
| 营收同比 | -5.0% | 43.0% |
| 净利润同比 | -33.3% | -31.2% |
| 每股收益（稀释后） | $0.16 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AOUTRGNX
| Q4 25 | $57.2M | $30.3M | ||
| Q3 25 | $29.7M | $29.7M | ||
| Q2 25 | $61.9M | $21.4M | ||
| Q1 25 | $58.5M | $89.0M | ||
| Q4 24 | $60.2M | $21.2M | ||
| Q3 24 | $41.6M | $24.2M | ||
| Q2 24 | $46.3M | $22.3M | ||
| Q1 24 | $53.4M | $15.6M |
净利润AOUTRGNX
| Q4 25 | $2.1M | $-67.1M | ||
| Q3 25 | $-6.8M | $-61.9M | ||
| Q2 25 | $-992.0K | $-70.9M | ||
| Q1 25 | $169.0K | $6.1M | ||
| Q4 24 | $3.1M | $-51.2M | ||
| Q3 24 | $-2.4M | $-59.6M | ||
| Q2 24 | $-5.3M | $-53.0M | ||
| Q1 24 | $-2.9M | $-63.3M |
毛利率AOUTRGNX
| Q4 25 | 45.6% | — | ||
| Q3 25 | 46.7% | — | ||
| Q2 25 | 40.9% | — | ||
| Q1 25 | 44.7% | — | ||
| Q4 24 | 48.0% | 70.2% | ||
| Q3 24 | 45.4% | 48.8% | ||
| Q2 24 | 41.9% | 52.5% | ||
| Q1 24 | 42.7% | 72.6% |
营业利润率AOUTRGNX
| Q4 25 | 3.7% | -190.0% | ||
| Q3 25 | -23.0% | -176.3% | ||
| Q2 25 | -1.5% | -296.3% | ||
| Q1 25 | 0.5% | 13.6% | ||
| Q4 24 | 5.1% | -242.1% | ||
| Q3 24 | -6.2% | -256.6% | ||
| Q2 24 | -11.9% | -251.3% | ||
| Q1 24 | -5.4% | -408.8% |
净利率AOUTRGNX
| Q4 25 | 3.6% | -221.3% | ||
| Q3 25 | -23.0% | -208.3% | ||
| Q2 25 | -1.6% | -331.8% | ||
| Q1 25 | 0.3% | 6.8% | ||
| Q4 24 | 5.2% | -241.3% | ||
| Q3 24 | -5.7% | -246.3% | ||
| Q2 24 | -11.5% | -237.7% | ||
| Q1 24 | -5.4% | -405.4% |
每股收益（稀释后）AOUTRGNX
| Q4 25 | $0.16 | $-1.30 | ||
| Q3 25 | $-0.54 | $-1.20 | ||
| Q2 25 | $-0.08 | $-1.38 | ||
| Q1 25 | $0.01 | $0.12 | ||
| Q4 24 | $0.24 | $-0.99 | ||
| Q3 24 | $-0.18 | $-1.17 | ||
| Q2 24 | $-0.41 | $-1.05 | ||
| Q1 24 | $-0.23 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $170.4M | $102.7M |
| 总资产 | $240.9M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AOUTRGNX
| Q4 25 | $3.1M | $230.1M | ||
| Q3 25 | $17.8M | $274.2M | ||
| Q2 25 | $23.4M | $323.3M | ||
| Q1 25 | $17.1M | $267.9M | ||
| Q4 24 | $14.2M | $234.7M | ||
| Q3 24 | $23.5M | $255.5M | ||
| Q2 24 | $29.7M | $290.4M | ||
| Q1 24 | $15.9M | $338.7M |
股东权益AOUTRGNX
| Q4 25 | $170.4M | $102.7M | ||
| Q3 25 | $167.8M | $161.5M | ||
| Q2 25 | $177.6M | $213.7M | ||
| Q1 25 | $178.7M | $274.2M | ||
| Q4 24 | $178.9M | $259.7M | ||
| Q3 24 | $175.7M | $301.4M | ||
| Q2 24 | $177.9M | $348.3M | ||
| Q1 24 | $182.4M | $390.7M |
总资产AOUTRGNX
| Q4 25 | $240.9M | $453.0M | ||
| Q3 25 | $241.9M | $525.2M | ||
| Q2 25 | $246.4M | $581.0M | ||
| Q1 25 | $245.9M | $490.9M | ||
| Q4 24 | $254.1M | $466.0M | ||
| Q3 24 | $244.8M | $519.1M | ||
| Q2 24 | $240.6M | $569.4M | ||
| Q1 24 | $239.1M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-13.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | -24.6% | -174.0% |
| 资本支出强度资本支出/营收 | 1.3% | 1.7% |
| 现金转化率经营现金流/净利润 | -6.41× | — |
| 过去12个月自由现金流最近4个季度 | $-4.7M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流AOUTRGNX
| Q4 25 | $-13.3M | $-52.3M | ||
| Q3 25 | $-1.7M | $-56.0M | ||
| Q2 25 | $7.8M | $-49.3M | ||
| Q1 25 | $5.9M | $33.6M | ||
| Q4 24 | $-7.9M | $-31.6M | ||
| Q3 24 | $-4.4M | $-40.5M | ||
| Q2 24 | $14.7M | $-45.5M | ||
| Q1 24 | $13.0M | $-55.5M |
自由现金流AOUTRGNX
| Q4 25 | $-14.1M | $-52.8M | ||
| Q3 25 | $-2.0M | $-56.5M | ||
| Q2 25 | $7.2M | $-49.7M | ||
| Q1 25 | $4.2M | $32.6M | ||
| Q4 24 | $-8.0M | $-32.7M | ||
| Q3 24 | $-5.2M | $-40.9M | ||
| Q2 24 | $14.2M | $-46.0M | ||
| Q1 24 | $9.7M | $-56.0M |
自由现金流率AOUTRGNX
| Q4 25 | -24.6% | -174.0% | ||
| Q3 25 | -6.7% | -189.9% | ||
| Q2 25 | 11.6% | -232.8% | ||
| Q1 25 | 7.2% | 36.6% | ||
| Q4 24 | -13.3% | -154.2% | ||
| Q3 24 | -12.5% | -168.9% | ||
| Q2 24 | 30.6% | -206.2% | ||
| Q1 24 | 18.2% | -358.5% |
资本支出强度AOUTRGNX
| Q4 25 | 1.3% | 1.7% | ||
| Q3 25 | 1.0% | 1.7% | ||
| Q2 25 | 0.9% | 1.8% | ||
| Q1 25 | 2.9% | 1.2% | ||
| Q4 24 | 0.1% | 5.1% | ||
| Q3 24 | 2.0% | 1.3% | ||
| Q2 24 | 1.1% | 2.1% | ||
| Q1 24 | 6.2% | 3.6% |
现金转化率AOUTRGNX
| Q4 25 | -6.41× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 34.86× | 5.53× | ||
| Q4 24 | -2.55× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AOUT
| Traditional Channels Net Sales | $36.8M | 64% |
| E Commerce Channels Net Sales | $20.4M | 36% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
